{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:29:11Z","timestamp":1765546151125},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T00:00:00Z","timestamp":1479254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The purpose of the study is to analyze the impact of an intervention to disseminate safety alerts on the utilization of Aliskiren added to angiotensin converting enzyme inhibitor (ACEI) or an angiotensin\u2010receptor blocker (ARB).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Quasi\u2010experimental design (non\u2010randomized intervention) comparing the utilization of Aliskiren\u2009+\u2009ACEI or ARB in a primary care area\u2010intervention (PCA\u2010I) with a primary care area\u2010control (PCA\u2010C) following a safety alert.<\/jats:p><jats:p>All physicians were provided with a list of diabetic patients (DM) on Aliskiren\u2009+\u2009ACEI or ARB. Physicians in the PCA\u2010I received also a non\u2010DM patients list, a report with recommendations and information on the utilization of Aliskiren\u2009+\u2009ACEI or ARB in their area. Information was obtained from electronic medical records, period from May 2010 to December 2012. Interrupted time series analysis were used to assess the effect of the intervention on the number of patients on Aliskiren\u2009+\u2009ACEI or ARB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The number of DM receiving Aliskiren\u2009+\u2009ACEI or ARB at the time of the alert (23 December 2011) was 106 in the PCA\u2010I (91 non\u2010DM) and 45 in the PCA\u2010C (25 non\u2010DM). After the alert, a decreased in the number of patients on Aliskiren\u2009+\u2009ACEI or ARB was noted at both PCAs, although the average of daily treatments ended was significantly higher in the PCA\u2010I, both in the DM group (slope after alert: \u22120.81, 95%CI \u22120.91 to \u22120.71 vs. \u22120.30, 95%CI \u22120.37 to \u22120.22) as well as in the non\u2010DM group (\u22120.56, 95%CI \u22120.67 to \u22120.45 vs. \u22120.10 95%CI \u22120.17 to \u22120.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The prescription of Aliskiren\u2009+\u2009ACEI or ARB decreased at both PCAs, albeit such decreased was more significant at the PCA\u2010I. The intervention led to a more expeditious implementation of the safety alert recommendations. Copyright \u00a9 2016 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4136","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T04:13:14Z","timestamp":1479355994000},"page":"91-96","source":"Crossref","is-referenced-by-count":3,"title":["Impact of an intervention on the prescription of aliskiren after new evidence on safety reported"],"prefix":"10.1002","volume":"26","author":[{"given":"Isabel","family":"Rosich Mart\u00ed","sequence":"first","affiliation":[{"name":"Primary Care Service Alt Pened\u00e8s\u2010Garraf Catalan Health Institute  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Allepuz","sequence":"additional","affiliation":[{"name":"Primary Care Service Alt Pened\u00e8s\u2010Garraf Catalan Health Institute  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Rodriguez Palomar","sequence":"additional","affiliation":[{"name":"Primary Care Service Hospitalet del Llobregat Catalan Health Institute  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ortin Font","sequence":"additional","affiliation":[{"name":"Health Region of Terres de l'Ebre Catalan Health Institute  Tarragona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Soler Cera","sequence":"additional","affiliation":[{"name":"IASIST Consulting Services  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048286"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn721"},{"key":"e_1_2_7_5_1","unstructured":"Informe CANM. Aliskir\u00e8n. N\u00b0 17 Diciembre2008. Available athttp:\/\/www.gencat.cat\/ics\/professionals\/medicaments\/Aliskireno.htm. [1 January 2012]."},{"key":"e_1_2_7_6_1","unstructured":"Informe CANM. Aliskir\u00e8n\/hidroclorotiazida. N\u00b03 Mar\u00e72011. Available athttp:\/\/www.gencat.cat\/ics\/professionals\/medicaments\/Aliskireno_HCTZ.htm. [1 January 2012]."},{"key":"e_1_2_7_7_1","unstructured":"Nota de Seguretat AEMPS: aliskireno revaluaci\u00f3n del balance beneficio\u2010riesgo(23 diciembre2011). Available athttp:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2011\/NI\u2010MUH_28\u20102011.htm. [2 January 2012]."},{"key":"e_1_2_7_8_1","unstructured":"Nota de Seguretat AEMPS: Aliskireno Conclusiones de la Revaluaci\u00f3n del balance beneficio\u2010riesgo(Febrero2012). Available atwww.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2012\/docs\/NI\u2010MUH_03\u20102012.pdf. [1 January 2007]."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czr004"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/11599100-000000000-00000"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f403"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0213-9111(05)71404-7"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-5013(07)73247-8"},{"key":"e_1_2_7_14_1","first-page":"94","article-title":"Influencia de una nota de seguridad emitida por la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios en el uso de los principios activos t\u00f3picos pimecrolimus y tacrolimus","volume":"10","author":"Elizondo\u2010L\u00f3pez de Landache I","year":"2008","journal-title":"Pharm Care Esp"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2008.04.003"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/11316520-000000000-00000"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2009.10.012"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1157\/13080141"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1157\/13087333"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.11.978.36136"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-3-200402030-00009"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.291.1.47","article-title":"National use de postmenopausal hormone therapy annual trends and response to recent evidence","volume":"291","author":"Hersh AL","year":"2004","journal-title":"JAMA"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.985"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02502.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2003.12.019"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1273"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.071540"},{"key":"e_1_2_7_28_1","first-page":"523","article-title":"Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk\u2010warning events","volume":"14","author":"Starner CI","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181ef9d2b"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318245a160"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1157\/13075956"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0213-9111(05)71403-5"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta8060"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L488"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000259.pub3"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ebd.6400910"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4136","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T09:40:08Z","timestamp":1696498808000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,16]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1002\/pds.4136"],"URL":"https:\/\/doi.org\/10.1002\/pds.4136","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,16]]}}}